For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$110.57
Thesis
Kymera is a leading targeted-protein-degradation company applying its platform to immunology and inflammation — degrading disease-driving proteins (STAT6, IRAK4) that conventional small molecules struggle to drug, aiming for oral therapies that compete with injectable biologics. Pharma partnerships (e.g. Sanofi) have validated the platform and helped fund it.
The investment case is platform breadth: one degradation chemistry reused across many immunology targets, with oral convenience as the commercial wedge against biologics. Risks: clinical-stage with the binary readout risk that entails, competition across the degrader field, and value spread across early programs rather than an approved product.
Catalysts
- STAT6 degrader clinical readouts in atopic dermatitis / immunology
- IRAK4 and follow-on program progress
- Partnership economics and option exercises
- Oral-vs-biologic differentiation data
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jun 30Trial initiationClinicalTrials.gov
Phase 2 trial (NCT07217015) of KT-621 in moderate to severe atopic dermatitis updated to active, not recruiting.
- Jun 30Trial initiationClinicalTrials.gov
Phase 2 long-term extension study (NCT07677059) of KT-621 in asthma now recruiting participants.
- Jun 29Trial initiationClinicalTrials.gov
Kymera initiates Phase 2 trial (NCT07323654) of KT-621 in moderate to severe eosinophilic asthma; recruiting status.
- Jun 8LeadershipSEC
8-K filing (item 5.02) discloses officer or director changes at Kymera Therapeutics.
- May 18Trial initiationClinicalTrials.gov
Kymera initiates Phase 2 trial (NCT07217015) of KT-621 in moderate to severe atopic dermatitis; status recruiting.
- May 18Trial initiationClinicalTrials.gov
Phase 2 trial (NCT07323654) of KT-621 initiated in moderate to severe eosinophilic asthma; recruiting